Axiom MRC has updated all it's market research reports with the Economic Impact Analysis of COVID19 Pandemic on the market. Our team of analyst are following Comprehensive Three Dimensional (3D) Research Methodology along with large number primary interviews with key industry participants to bring insightful market reports to meet the current market requirements.
Lung cancer is type of cancer that initiate in the lungs. Cancer begins when cells in body ready to grow out of control. The bronchi are affected firstly in lung cancer and goes into parts of lungs like bronchioles or alveoli. The lung cancer has accounted for 606,520 deaths from lung cancer. It affects both men and women the women. The lung cancer is most common in women after the breast cancers. It takes approximately three to six months to kung cancer to double their sizes. Thereby it takes multiple years for typical lung cancer to reach size which can be diagnosed in chest X-ray. Non-small cell lung cancer has four main stages like stage 1 to 4.
The United States lung cancer diagnostic market is witnessing tremendous growth during the forecast period 2021-2027. The rising in prevalence of unhealthy lifestyles and new product launch is also gaining attention of United States lung cancer diagnostic market. The dynamic factors such as rise in awareness about lung cancer symptoms is propelling growth of United States lung cancer diagnostic market. High cigarette consumption rate is also boosting growth of United States lung cancer diagnostic market. However, cost of diagnosis is hindering the growth of United States lung cancer diagnostic market.
The exclusive COVID-19 impact analysis report by Axiom MRC provides a 3600 analysis of micro and macro-economic factors on the lung cancer diagnostic market. In addition, complete analysis of changes on lung cancer diagnostic expenditure, economic and international policies on supply and demand side. The report also studies the impact of pandemic on United States economies, international trade, business investments, GDP and marketing strategies of key players present in the market. The COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines.
The United States lung cancer diagnostic market is segmented into cancer type, diagnostic test and end user.
Based on cancer type, the United States lung cancer diagnostic market is segmented into small cell lung cancer and non-small cell lung cancer. In which small cell lung cancer is also contributing in the market growth. The small cell lung cancer is fast growing types of lung cancer. It is aggressive form of lung cancer which affect smokers mostly. It starts usually in bronchi (breathing tubes) and grows rapidly and creates large tumours along with spreading throughout the body.
Based on diagnostic test, the United States lung cancer diagnostic market is bifurcated into biomarkers test, imaging test, biopsy and other test. The biomarkers test is sub-categorised into the CA test, HER2 Test, ALK Test, Angiogenesis Inhibitors, KRAS mutation test. Likewise, Imaging test is also sub-segmented into computed tomography scan, positron emission tomography scan and chest x-ray. The biopsy sub-segmented into needle biopsy, bronchoscopy biopsy and open biopsy. The imaging test is also contributing to the growth of United States lung cancer diagnostic market. The increasing focus on early diagnosis is propelling growth of United States lung cancer diagnosis market. The rising population of early smokers is also boosting growth of United States lung cancer diagnosis market.
Based on end user, the United States lung cancer diagnostic market is categorised into hospital assisted labs, independent diagnostic laboratories and cancer research centres. In which independent diagnostic laboratories is also contributing to the growth of United States lung cancer diagnostic market. The rising prevalence of lung cancer is propelling growth of United States lung cancer diagnosis market. The increasing awareness regarding early diagnosis is also boosting growth of United States lung cancer diagnosis market.
The major key players operating in the lung cancer diagnostic market are Illumina Inc., Abbott, Thermo Fisher Scientific Inc., Qiagen, Quest Diagnostics Incorporated, Neogenomics, Nanostring Technologies Inc, Myriad Genetics Inc, Roche Holding Ag, Danaher, Agilent Technologies, Astrazeneca, Sanofi, Janssen Pharmaceuticals, Biomérieux Sa, Ge Healthcare, Hologic, Koninklijke Philips N.V, Biotheranostics and Exact Sciences among others.
March 2021 Agilent Technologies Inc., entered into a definitive agreement to acquire Resolution Bioscience Inc., a leader in the development and commercialization of next-generation sequencing (NGS)-based precision oncology solutions.
March 2020, Thermo Fisher Scientific entered into a partnership with Janssen Biotech, a part of Johnson & Johnson to develop lung cancer companion diagnostic.
July 2020, AnchorDx, a leading biotechnology company developing novel NGS-based early cancer detection and disease monitoring tests, entered into a multi-year collaboration with the Lung Cancer Initiative at Johnson & Johnson to conduct a lung cancer study.
June 2019, Roche, launched in-vitro lung cancer diagnostic test VENTANA ROS1 (SP384) to target ROS1 positive lung cancer.
The report analyses the lung cancer diagnostic market based on cancer type, diagnostic test and end user. Various types of lung cancers covered in the lung cancer diagnostic market are small cell lung cancer and non-small cell lung cancers. By diagnostic test, the market is segmented into the biomarkers test, imaging test, biopsy and others. Based on end users, the market is segmented into the hospital associated labs, independent diagnostic laboratories and cancer research institutes. The report also imparts the impact of COVID-19 on the lung cancer diagnostic market and it founds that the COVID-19 has almost affected every market is healthcare industries positively or negatively. The lung cancer diagnostic market is also experienced somewhat negative impact of COVID-19. As due to lockdown, physicians where treating only emergency cases whereby the other diagnostic procedure where postponed. The lung cancer patients are at higher risk of COVID-19 infections. After the slight relaxation the market is growing at significant rates. The market is get resumed with use of mask and maintaining social distancing as per the government guidelines. The report also analyses the major key players operating in the market.
Why to buy this report
